Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Single-Arm, Clinical Study of TQB2450 Plus Anlotinib in EGFR-Positive Non-Small Cell Lung Cancer Patients After Failure of EGFR TKI Therapy

Next Previous
Trial Profile

A Multicenter, Single-Arm, Clinical Study of TQB2450 Plus Anlotinib in EGFR-Positive Non-Small Cell Lung Cancer Patients After Failure of EGFR TKI Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER-L038

    • Most Recent Events

    • 12 Sep 2023 Results (data cut-off as of 1 Feb 2023 , n= 55 ) of updated the latest efficacy and safety data , presented at the 24th World Conference on Lung Cancer
    • 08 Jul 2021 New trial record
    • 08 Jun 2021 Status changed from not yet recruiting to recruiting as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top